Glenview Trust Co Has $95.89 Million Stake in AbbVie Inc. $ABBV

Glenview Trust Co cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 414,149 shares of the company’s stock after selling 7,330 shares during the quarter. AbbVie comprises 1.5% of Glenview Trust Co’s portfolio, making the stock its 18th biggest holding. Glenview Trust Co’s holdings in AbbVie were worth $95,892,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ABBV. Ellenbecker Investment Group lifted its stake in shares of AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA lifted its position in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after acquiring an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC boosted its holdings in shares of AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares during the period. Centennial Wealth Advisory LLC grew its position in shares of AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after purchasing an additional 45 shares during the last quarter. Finally, Willner & Heller LLC grew its holdings in AbbVie by 0.6% in the 3rd quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after buying an additional 46 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

AbbVie stock opened at $231.57 on Tuesday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market capitalization of $409.28 billion, a P/E ratio of 98.12, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. The stock has a fifty day moving average of $223.73 and a 200-day moving average of $221.37.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ABBV. Guggenheim lifted their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, UBS Group lowered their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.